Difference between revisions of "Finasteride (Proscar)"
Jump to navigation
Jump to search
m |
m |
||
| Line 13: | Line 13: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| + | [[Category:Endocrine therapy]] | ||
[[Category:Antiandrogens]] | [[Category:Antiandrogens]] | ||
[[Category:5 alpha-reductase inhibitors]] | [[Category:5 alpha-reductase inhibitors]] | ||
[[Category:Prostate cancer medications]] | [[Category:Prostate cancer medications]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 1992]] | ||
Revision as of 02:42, 4 November 2014
General information
Class/mechanism: 5 alpha-reductase inhibitor; inhibits conversion of testosterone to dihydrotestosterone (DHT). Specifically and competitively inhibits Type II 5α-reductase by forming a stable enzyme-drug complex.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]